China's implementation of the drug markup rate control policy, the government through the control of public medical institutions of the drug procurement price and drug markup rate to control the policy of its drug retail price, including the price markup of 15%, zero differential rate and differential markup and other policies. According to the CPPCC member of the All-China Federation of Industry and Commerce, such a policy will cause the following problems: the higher the procurement price of drugs for public hospitals, the more profit they will make. Under the reverse incentive of the drug markup rate control policy, doctors prescribe more drugs and expensive drugs so that hospitals can obtain more drug markup income. This phenomenon also leads to a certain degree of doctors receiving more serious phenomenon of kickbacks.
The National Federation of Industry and Commerce CPPCC proposal suggests: cancel the policy of 15% price increase, the implementation of only the maximum retail price of drugs and dynamic adjustment of the policy, the return of the procurement of medical institutions, the government focus on good supervision. The procurement orientation of medical institutions will return to normal, and purchase drugs at the bottom price, in the case of the bottom price without rebates, doctors will not be able to overuse drugs. Drug production and management enterprises also do not need to carry out "high pricing, large rebates" vicious competition, but will be from the price, service, efficiency, management and other aspects of competition, conducive to the standardization of the market order and improve the concentration of the industry. At the same time, the guiding price of drugs can make patients and health insurance to pay less for drugs. At the same time, the government can take advantage of the role of the market mechanism, access to real information on drug prices, according to which the maximum retail price of medicines for dynamic adjustment